Platelet function testing in cardiovascular diseases

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 132-137

  Michelson, Alan D ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Center for Platelet Function Studies   (United States)

Author keywords

Aspirin; Clopidogrel; GPIIb IIIa antagonists; Platelets; Tests

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; TICLOPIDINE; TIROFIBAN;

ANGINA PECTORIS; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CORONARY ARTERY THROMBOSIS; DRUG ACTIVITY; DRUG RESISTANCE; HEMOSTASIS; HUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

CARDIOVASCULAR DISEASES; DRUG MONITORING; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROGNOSIS;

EID: 29244473847     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331390186     Document Type: Article

References (25)

1. Michelson AD. Platelets. New York: Academic Press/Elsevier Science; 2002.
2. Ruggeri ZM. Platelets in atherothrombosis. Nature Med 2002;8:1227-1234.
3. Michelson AD, Barnard MR, Krueger LA, et al. Flow cytometry. In: Michelson AD, editor. Platelets. New York: Academic Press/Elsevier Science; 2002. pp 297-315.
4. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998;98:1721-1727.
5. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
6. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
7. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
8. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
9. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-2268.
10. Lanza GA, Sestito A, Iacovella S, et al. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation 2003;107:1378-1382.
11. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004, in press.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
13. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
14. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
15. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
16. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
17. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126.
18. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66.
19. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
20. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578.
21. Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003;108:2971-2973.
22. Pollack A. For some, aspirin may not help hearts. New York Times, page F1, July 20, 2004.
23. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
24. Woulfe D, Yang J, Prevost N, et al. Signal transduction during the initiation, extension, and perpetuation of platelet plug formation. In: Michelson AD, editor. Platelets. New York: Academic Press/Elsevier Science; 2002. pp 197-213.
25. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744.